Leerink Partnrs Brokers Lower Earnings Estimates for Biogen

Biogen Inc. (NASDAQ:BIIB) – Research analysts at Leerink Partnrs cut their Q1 2025 EPS estimates for Biogen in a note issued to investors on Sunday, April 13th. Leerink Partnrs analyst M. Goodman now forecasts that the biotechnology company will post earnings of $2.70 per share for the quarter, down from their prior forecast of $3.84. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. Leerink Partnrs also issued estimates for Biogen’s FY2027 earnings at $16.45 EPS and FY2028 earnings at $17.95 EPS.

BIIB has been the subject of a number of other research reports. BMO Capital Markets lowered their price target on Biogen from $156.00 to $139.00 and set a “market perform” rating for the company in a research report on Thursday, February 13th. Wells Fargo & Company decreased their target price on Biogen from $165.00 to $140.00 and set an “equal weight” rating for the company in a report on Thursday, February 13th. Truist Financial cut their price target on shares of Biogen from $220.00 to $210.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. Argus downgraded shares of Biogen from a “buy” rating to a “hold” rating in a research note on Friday, April 4th. Finally, William Blair reissued an “outperform” rating on shares of Biogen in a research note on Monday, January 13th. Eighteen analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $213.15.

Biogen Stock Down 1.9 %

Shares of NASDAQ BIIB opened at $116.98 on Wednesday. The stock has a market capitalization of $17.12 billion, a PE ratio of 10.45, a P/E/G ratio of 1.51 and a beta of 0.06. The company has a quick ratio of 0.90, a current ratio of 1.35 and a debt-to-equity ratio of 0.27. The firm has a fifty day moving average of $135.71 and a 200-day moving average of $152.96. Biogen has a 52-week low of $110.04 and a 52-week high of $238.00.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%.

Institutional Investors Weigh In On Biogen

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Lee Danner & Bass Inc. bought a new stake in shares of Biogen in the fourth quarter valued at about $25,000. Larson Financial Group LLC grew its holdings in shares of Biogen by 640.9% during the 4th quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 141 shares in the last quarter. Colonial Trust Co SC increased its position in shares of Biogen by 9,300.0% during the fourth quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 186 shares during the period. SRS Capital Advisors Inc. acquired a new position in shares of Biogen in the fourth quarter valued at $33,000. Finally, OFI Invest Asset Management bought a new position in Biogen in the fourth quarter worth $32,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Biogen news, Director Stephen A. Sherwin sold 8,760 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the transaction, the director now owns 11,318 shares in the company, valued at $1,697,926.36. This trade represents a 43.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.